Medical - Devices
Compare Stocks
2 / 10Stock Comparison
MASS vs WAT
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Diagnostics & Research
MASS vs WAT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Devices | Medical - Diagnostics & Research |
| Market Cap | $302M | $22.83B |
| Revenue (TTM) | $58M | $3.77B |
| Net Income (TTM) | $-36M | $449M |
| Gross Margin | 51.5% | 55.0% |
| Operating Margin | -71.4% | 17.1% |
| Forward P/E | 15.0x | 24.4x |
| Total Debt | $17M | $1.41B |
| Cash & Equiv. | $113M | $588M |
MASS vs WAT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Dec 20 | May 26 | Return |
|---|---|---|---|
| 908 Devices Inc. (MASS) | 100 | 14.2 | -85.8% |
| Waters Corporation (WAT) | 100 | 141.6 | +41.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MASS vs WAT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
MASS is the clearest fit if your priority is growth exposure.
- Rev growth -5.8%, EPS growth 125.5%, 3Y rev CAGR 6.3%
- Lower P/E (15.0x vs 24.4x)
- +48.8% vs WAT's +1.4%
WAT carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 1 yrs, beta 1.07
- 162.0% 10Y total return vs MASS's -83.5%
- Lower volatility, beta 1.07, Low D/E 55.0%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 7.0% revenue growth vs MASS's -5.8% | |
| Value | Lower P/E (15.0x vs 24.4x) | |
| Quality / Margins | 11.9% margin vs MASS's -62.4% | |
| Stability / Safety | Beta 1.07 vs MASS's 1.38 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +48.8% vs WAT's +1.4% | |
| Efficiency (ROA) | 4.6% ROA vs MASS's -19.0%, ROIC 20.3% vs -47.5% |
MASS vs WAT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
MASS vs WAT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
WAT leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
WAT is the larger business by revenue, generating $3.8B annually — 65.2x MASS's $58M. WAT is the more profitable business, keeping 11.9% of every revenue dollar as net income compared to MASS's -62.4%. On growth, WAT holds the edge at +91.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $58M | $3.8B |
| EBITDAEarnings before interest/tax | -$38M | $953M |
| Net IncomeAfter-tax profit | -$36M | $449M |
| Free Cash FlowCash after capex | -$8M | $264M |
| Gross MarginGross profit ÷ Revenue | +51.5% | +55.0% |
| Operating MarginEBIT ÷ Revenue | -71.4% | +17.1% |
| Net MarginNet income ÷ Revenue | -62.4% | +11.9% |
| FCF MarginFCF ÷ Revenue | -14.4% | +7.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +13.6% | +91.5% |
| EPS Growth (YoY)Latest quarter vs prior year | -126.0% | -142.9% |
Valuation Metrics
MASS leads this category, winning 3 of 3 comparable metrics.
Valuation Metrics
At 15.0x trailing earnings, MASS trades at a 54% valuation discount to WAT's 32.6x P/E.
| Metric | ||
|---|---|---|
| Market CapShares × price | $302M | $22.8B |
| Enterprise ValueMkt cap + debt − cash | $206M | $23.7B |
| Trailing P/EPrice ÷ TTM EPS | 14.96x | 32.55x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 24.36x |
| PEG RatioP/E ÷ EPS growth rate | — | 6.29x |
| EV / EBITDAEnterprise value multiple | — | 21.51x |
| Price / SalesMarket cap ÷ Revenue | 5.37x | 7.21x |
| Price / BookPrice ÷ Book value/share | 2.19x | 8.17x |
| Price / FCFMarket cap ÷ FCF | — | 42.30x |
Profitability & Efficiency
WAT leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
WAT delivers a 8.0% return on equity — every $100 of shareholder capital generates $8 in annual profit, vs $-26 for MASS. MASS carries lower financial leverage with a 0.12x debt-to-equity ratio, signaling a more conservative balance sheet compared to WAT's 0.55x.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -25.6% | +8.0% |
| ROA (TTM)Return on assets | -19.0% | +4.6% |
| ROICReturn on invested capital | -47.5% | +20.3% |
| ROCEReturn on capital employed | -27.2% | +18.5% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 |
| Debt / EquityFinancial leverage | 0.12x | 0.55x |
| Net DebtTotal debt minus cash | -$96M | $820M |
| Cash & Equiv.Liquid assets | $113M | $588M |
| Total DebtShort + long-term debt | $17M | $1.4B |
| Interest CoverageEBIT ÷ Interest expense | — | 6.72x |
Total Returns (Dividends Reinvested)
WAT leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in WAT five years ago would be worth $11,133 today (with dividends reinvested), compared to $1,601 for MASS. Over the past 12 months, MASS leads with a +48.8% total return vs WAT's +1.4%. The 3-year compound annual growth rate (CAGR) favors WAT at 5.7% vs MASS's 4.2% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +58.7% | -8.3% |
| 1-Year ReturnPast 12 months | +48.8% | +1.4% |
| 3-Year ReturnCumulative with dividends | +13.2% | +18.1% |
| 5-Year ReturnCumulative with dividends | -84.0% | +11.3% |
| 10-Year ReturnCumulative with dividends | -83.5% | +162.0% |
| CAGR (3Y)Annualised 3-year return | +4.2% | +5.7% |
Risk & Volatility
Evenly matched — MASS and WAT each lead in 1 of 2 comparable metrics.
Risk & Volatility
WAT is the less volatile stock with a 1.07 beta — it tends to amplify market swings less than MASS's 1.38 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.38x | 1.07x |
| 52-Week HighHighest price in past year | $9.34 | $414.15 |
| 52-Week LowLowest price in past year | $4.20 | $275.05 |
| % of 52W HighCurrent price vs 52-week peak | +86.5% | +84.6% |
| RSI (14)Momentum oscillator 0–100 | 69.3 | 64.9 |
| Avg Volume (50D)Average daily shares traded | 272K | 999K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates MASS as "Buy" and WAT as "Hold".
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold |
| Price TargetConsensus 12-month target | — | $402.57 |
| # AnalystsCovering analysts | 5 | 34 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.1% |
WAT leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). MASS leads in 1 (Valuation Metrics). 1 tied.
MASS vs WAT: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is MASS or WAT a better buy right now?
For growth investors, Waters Corporation (WAT) is the stronger pick with 7.
0% revenue growth year-over-year, versus -5. 8% for 908 Devices Inc. (MASS). 908 Devices Inc. (MASS) offers the better valuation at 15. 0x trailing P/E, making it the more compelling value choice. Analysts rate 908 Devices Inc. (MASS) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — MASS or WAT?
On trailing P/E, 908 Devices Inc.
(MASS) is the cheapest at 15. 0x versus Waters Corporation at 32. 6x.
03Which is the better long-term investment — MASS or WAT?
Over the past 5 years, Waters Corporation (WAT) delivered a total return of +11.
3%, compared to -84. 0% for 908 Devices Inc. (MASS). Over 10 years, the gap is even starker: WAT returned +162. 0% versus MASS's -83. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — MASS or WAT?
By beta (market sensitivity over 5 years), Waters Corporation (WAT) is the lower-risk stock at 1.
07β versus 908 Devices Inc. 's 1. 38β — meaning MASS is approximately 29% more volatile than WAT relative to the S&P 500. On balance sheet safety, 908 Devices Inc. (MASS) carries a lower debt/equity ratio of 12% versus 55% for Waters Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — MASS or WAT?
By revenue growth (latest reported year), Waters Corporation (WAT) is pulling ahead at 7.
0% versus -5. 8% for 908 Devices Inc. (MASS). On earnings-per-share growth, the picture is similar: 908 Devices Inc. grew EPS 125. 5% year-over-year, compared to 0. 5% for Waters Corporation. Over a 3-year CAGR, MASS leads at 6. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — MASS or WAT?
908 Devices Inc.
(MASS) is the more profitable company, earning 34. 7% net margin versus 20. 3% for Waters Corporation — meaning it keeps 34. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: WAT leads at 28. 2% versus -70. 1% for MASS. At the gross margin level — before operating expenses — WAT leads at 57. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Which pays a better dividend — MASS or WAT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is MASS or WAT better for a retirement portfolio?
For long-horizon retirement investors, Waters Corporation (WAT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
07), +162. 0% 10Y return). Both have compounded well over 10 years (WAT: +162. 0%, MASS: -83. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between MASS and WAT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: MASS is a small-cap deep-value stock; WAT is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.